CVE-2026-17003
Multiple vulnerabilities have been discovered in IBM products. Some of them allow an attacker to cause remote arbitrary code execution, privilege escalation and remote denial of service.
CSIRTS triage
- What
- Multiple vulnerabilities in IBM products allow remote arbitrary code execution, privilege escalation, and denial of service.
- Who is affected
- IBM product deployments across multiple product lines.
- Urgency
- Critical: exploitation is already occurring in the wild.
- Action
- Review IBM security advisories for affected products, identify which are deployed, and apply patches immediately for any actively exploited CVEs.
AI-assisted analysis generated from the source advisory — verify against the original.
⚡ Watch CVE-2026-17003
Get an email if CVE-2026-17003 is added to CISA KEV, gains public exploit code, or a new advisory cites it — max one per day, one-click unsubscribe.
Exploitation outlook
- Low exploitation risk0.43% 30-day exploitation probability — currently an unlikely target, but scores change as exploit code circulates. Riskier than 36% of all EPSS-scored CVEs.
Advisory coverage (2)
- unknownexploitedMultiple vulnerabilities in IBM products (August 21, 2026)cert-fr-avis · 2026-08-21
- highCVE-2026-17003: IBM AIX 7.2, and 7.3 and IBM PowerVM VIOS 4.1 could allow a remote attacker to compromise the …nvd · 2026-08-20
External references
Embed the live status
— this badge updates automatically when the KEV or exploit status changes. How to embed it →
[](https://www.csirts.com/cve/CVE-2026-17003)